Avamys Nasal Spray 27.5 mcgspray

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

Fluticasone Furoate (micronised)

から入手可能:

GLAXOSMITHKLINE PTE LTD

ATCコード:

R01AD12

投薬量:

0.0275mg/spray

医薬品形態:

SPRAY, SUSPENSION

構図:

Fluticasone Furoate (micronised) 0.0275mg/spray

投与経路:

NASAL

処方タイプ:

Prescription Only

製:

Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)

認証ステータス:

ACTIVE

承認日:

2009-06-23

情報リーフレット

 
1 

AVAMYS
TM
 NASAL SPRAY 
FLUTICASONE FUROATE 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
_AVAMYS_ Nasal Spray is a white, uniform suspension contained in
an amber glass bottle, 
fitted with a metering (50 microlitres) atomising spray pump.
 This inner pack is 
incorporated within a predominantly off-white plastic device with
a blue side-actuated 
lever and a lid which contains a stopper.  Each
spray of the suspension delivers 
approximately 27.5 micrograms of micronised
fluticasone furoate as an ex-device dose.  
PHARMACEUTICAL FORM 
Nasal spray, suspension. 
CLINICAL PARTICULARS 
INDICATIONS 

_AVAMYS_ Nasal Spray is indicated
for the treatment of the symptoms of allergic rhinitis in 
patients 6 years of age and older. 
DOSAGE AND ADMINISTRATION 
_AVAMYS_ Nasal Spray is for administration
by the intranasal route only. For full 
therapeutic benefit regular scheduled usage is recommended.
Onset of action has been 
observed as early as 8 hours after initial administration.
It may take several days of 
treatment to achieve maximum benefit. An absence of an immediate
effect should be 
explained to the patient _(see Clinical Studies)._ 
POPULATIONS 
For the treatment of seasonal allergic rhinitis and perennial
allergic rhinitis: 
ADULTS AND ADOLESCENTS (12 YEARS AND OLDER) 
The recommended starting dosage is 2 sprays (27.5
micrograms per spray) in each nostril 
once daily (total daily dose, 110 micrograms). 
Once adequate control of symptoms is achieved, dose reduction
to 1 spray in each nostril 
once daily (total daily dose, 55
micrograms) may be effective for maintenance. 
CHILDREN (6 TO 11 YEARS) 

2 

The recommended starting dosage is 1 spray (27.5
micrograms per spray) in each nostril 
once daily (total daily dose, 55 micrograms). 
Patients not adequately responding to 1 spray in each
nostril once daily (tot

製品の特徴

1
AVAMYS NASAL SPRAY
FLUTICASONE FUROATE
QUALITATIVE AND QUANTITATIVE COMPOSITION
_AVAMYS_
Nasal Spray is a white, uniform suspension contained in an amber glass
bottle,
fitted with a metering (50 microlitres) atomising spray pump. This
inner pack is
incorporated within a predominantly off-white plastic device with a
blue side-actuated
lever and a lid which contains a stopper. Each spray of the suspension
delivers
approximately 27.5 micrograms of micronised fluticasone furoate as an
ex-device dose.
PHARMACEUTICAL FORM
Nasal spray, suspension.
CLINICAL PARTICULARS
INDICATIONS
_AVAMYS_
Nasal Spray is indicated for the treatment of the symptoms of allergic
rhinitis in
patients 2 years of age and older.
DOSAGE AND ADMINISTRATION
_AVAMYS_
Nasal Spray is for administration by the intranasal route only. For
full
therapeutic benefit regular scheduled usage is recommended. Onset of
action has been
observed as early as 8 hours after initial administration. It may take
several days of
treatment to achieve maximum benefit. An absence of an immediate
effect should be
explained to the patient
_(see Clinical Studies)._
POPULATIONS
For the treatment of seasonal allergic rhinitis and perennial allergic
rhinitis:
ADULTS AND ADOLESCENTS (12 YEARS AND OLDER)
The recommended starting dosage is 2 sprays (27.5 micrograms per
spray) in each nostril
once daily (total daily dose, 110 micrograms).
Once adequate control of symptoms is achieved, dose reduction to 1
spray in each nostril
once daily (total daily dose, 55 micrograms) may be effective for
maintenance.
CHILDREN (2 TO 11 YEARS)
The recommended starting dosage is 1 spray (27.5 micrograms per spray)
in each nostril
once daily (total daily dose, 55 micrograms).
Patients not adequately responding to 1 spray in each nostril once
daily (total daily dose,
55 micrograms) may use 2 sprays in each nostril once daily (total
daily dose, 110
2
micrograms). Once adequate control of symptoms is achieved, dose
reduction to 1 spray
in each nostril once daily (total daily dose, 55 micrograms) is
re